Status:
COMPLETED
Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
Bandim Health Project
Hospital Nacional Simao Mendes, Bissau
Conditions:
Malaria
Eligibility:
All Genders
18-24 years
Phase:
PHASE3
Brief Summary
BCG vaccine is given at or shortly after birth in many developing countries to prevent tuberculosis. In Guinea Bissau, it has been shown that its protective effect against death is greater than would ...
Detailed Description
Background Studies undertaken in Guinea Bissau have shown that the protective effect of BCG vaccine against death in young children is greater than would be expected from its effect in preventing tub...
Eligibility Criteria
Inclusion
- Age more than 18 months and less than 24 months
- Previous BCG vaccination
Exclusion
- Mantoux skin reaction \> 14 mm
- Chronic underlying illness
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00131794
Start Date
January 1 2003
End Date
December 1 2003
Last Update
September 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bandim Health Project
Bissau, Guinea-Bissau, 1004 Bissau CODEX